- Home
- INZY vs IDR Comparison
INZY vs IDR Comparison
Compare INZY & IDR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- IDR
- Stock Information
- Founded
- INZY 2015
- IDR 1996
- Country
- INZY United States
- IDR United States
- Employees
- INZY N/A
- IDR N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- IDR Precious Metals
- Sector
- INZY Health Care
- IDR Basic Materials
- Exchange
- INZY Nasdaq
- IDR Nasdaq
- Market Cap
- INZY 188.2M
- IDR 142.7M
- IPO Year
- INZY 2020
- IDR N/A
- Fundamental
- Price
- INZY $1.36
- IDR $13.65
- Analyst Decision
- INZY Strong Buy
- IDR Strong Buy
- Analyst Count
- INZY 8
- IDR 1
- Target Price
- INZY $17.75
- IDR $14.00
- AVG Volume (30 Days)
- INZY 1.0M
- IDR 142.6K
- Earning Date
- INZY 03-11-2025
- IDR 03-24-2025
- Dividend Yield
- INZY N/A
- IDR N/A
- EPS Growth
- INZY N/A
- IDR 344.27
- EPS
- INZY N/A
- IDR 0.52
- Revenue
- INZY N/A
- IDR $21,955,008.00
- Revenue This Year
- INZY N/A
- IDR $86.37
- Revenue Next Year
- INZY N/A
- IDR $11.11
- P/E Ratio
- INZY N/A
- IDR $26.67
- Revenue Growth
- INZY N/A
- IDR 64.93
- 52 Week Low
- INZY $1.24
- IDR $6.40
- 52 Week High
- INZY $7.80
- IDR $18.35
- Technical
- Relative Strength Index (RSI)
- INZY 29.28
- IDR 62.01
- Support Level
- INZY $1.35
- IDR $12.46
- Resistance Level
- INZY $1.62
- IDR $13.40
- Average True Range (ATR)
- INZY 0.13
- IDR 0.65
- MACD
- INZY 0.04
- IDR 0.22
- Stochastic Oscillator
- INZY 32.89
- IDR 80.00
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About IDR Idaho Strategic Resources Inc.
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. It produces gold at the Golden Chest Mine. In addition to gold and gold production, the company maintains a strategic and domestic presence in the Critical Minerals sector and is focused on advancing its officially recognized Lemhi Pass, Diamond Creek, and Roberts Rare Earth Element projects in central Idaho.